Review



untargeted global plasma metabolomics profiling  (Metabolon Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Metabolon Inc untargeted global plasma metabolomics profiling
    Untargeted Global Plasma Metabolomics Profiling, supplied by Metabolon Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/untargeted+global+plasma+metabolomics+profiling/pm41741793-253-0-8?v=Metabolon+Inc
    Average 86 stars, based on 1 article reviews
    untargeted global plasma metabolomics profiling - by Bioz Stars, 2026-08
    86/100 stars

    Images



    Similar Products

    untargeted global plasma metabolomics profiling  (Metabolon Inc)
    86
    Metabolon Inc untargeted global plasma metabolomics profiling
    Untargeted Global Plasma Metabolomics Profiling, supplied by Metabolon Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/untargeted+global+plasma+metabolomics+profiling/pm41741793-253-0-8?v=Metabolon+Inc
    Average 86 stars, based on 1 article reviews
    untargeted global plasma metabolomics profiling - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    untargeted global plasma metabolomic profiling  (Metabolon Inc)
    90
    Metabolon Inc untargeted global plasma metabolomic profiling
    Overall study design. The study utilizes patients from the MGB Biobank that were infected with SARS-CoV-2 at some point between the start of the pandemic (01/01/2020) through 10/27/2020 to generate the Longitudinal EMR and Omics COVID-19 Cohort (LEOCC). After exclusions, 592 patients were included, with 455 patients having plasma samples prior to COVID-19 infection, and 137 patients having one or more plasma samples during/after COVID-19 infection. <t>Metabolomic</t> profiles were generated on all plasma samples. We used profiling prior to COVID-19 infection to cluster individuals into three prospective metabolomic endotypes and assessed their relationship with both COVID-19 severity and influenza incidence/recurrence. We further evaluated the generalizability of these findings to metabolomic profiling during and after acute COVID-19 infection and evaluated the associations with COVID-19 severity and influenza infection/recurrence.
    Untargeted Global Plasma Metabolomic Profiling, supplied by Metabolon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/untargeted+global+plasma+metabolomics+profiling/pmc10518609-232-0-8?v=Metabolon+Inc
    Average 90 stars, based on 1 article reviews
    untargeted global plasma metabolomic profiling - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Overall study design. The study utilizes patients from the MGB Biobank that were infected with SARS-CoV-2 at some point between the start of the pandemic (01/01/2020) through 10/27/2020 to generate the Longitudinal EMR and Omics COVID-19 Cohort (LEOCC). After exclusions, 592 patients were included, with 455 patients having plasma samples prior to COVID-19 infection, and 137 patients having one or more plasma samples during/after COVID-19 infection. Metabolomic profiles were generated on all plasma samples. We used profiling prior to COVID-19 infection to cluster individuals into three prospective metabolomic endotypes and assessed their relationship with both COVID-19 severity and influenza incidence/recurrence. We further evaluated the generalizability of these findings to metabolomic profiling during and after acute COVID-19 infection and evaluated the associations with COVID-19 severity and influenza infection/recurrence.

    Journal: eBioMedicine

    Article Title: The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases

    doi: 10.1016/j.ebiom.2023.104791

    Figure Lengend Snippet: Overall study design. The study utilizes patients from the MGB Biobank that were infected with SARS-CoV-2 at some point between the start of the pandemic (01/01/2020) through 10/27/2020 to generate the Longitudinal EMR and Omics COVID-19 Cohort (LEOCC). After exclusions, 592 patients were included, with 455 patients having plasma samples prior to COVID-19 infection, and 137 patients having one or more plasma samples during/after COVID-19 infection. Metabolomic profiles were generated on all plasma samples. We used profiling prior to COVID-19 infection to cluster individuals into three prospective metabolomic endotypes and assessed their relationship with both COVID-19 severity and influenza incidence/recurrence. We further evaluated the generalizability of these findings to metabolomic profiling during and after acute COVID-19 infection and evaluated the associations with COVID-19 severity and influenza infection/recurrence.

    Article Snippet: Untargeted global plasma metabolomic profiling was generated by Metabolon Inc. Coefficients of variation were measured in blinded quality control (QC) samples randomly distributed among study samples.

    Techniques: Infection, Clinical Proteomics, Generated

    Phenotypes by metabolomic endotypes, including descriptive characteristics, comorbidity diseases, COVID-19 severity, influenza incidence and recurrence, and lab tests.

    Journal: eBioMedicine

    Article Title: The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases

    doi: 10.1016/j.ebiom.2023.104791

    Figure Lengend Snippet: Phenotypes by metabolomic endotypes, including descriptive characteristics, comorbidity diseases, COVID-19 severity, influenza incidence and recurrence, and lab tests.

    Article Snippet: Untargeted global plasma metabolomic profiling was generated by Metabolon Inc. Coefficients of variation were measured in blinded quality control (QC) samples randomly distributed among study samples.

    Techniques:

    Associations between COVID-19 severity and influenza infection with metabolomic endotypes . Chi-square tests determined the differences in clinical characteristics across metabolomic endotypes for categorical variables (COVID severity variables: severity, ICU admission, deceased; Influenza variable: Influenza existence) and one-way analysis of variance (ANOVA) tests for continuous variables (Influenza counts). Severity had four categories for a response after COVID-19 infection: No hospitalization, Inpatient/Emergency visit, ICU/Mechanical Ventilation/Intubation, and Deceased. The ICU Admission was a binary variable generated based on whether the patient had ICU admission or not: less severe (0) contained No hospitalization and Inpatient/Emergency visit, and more severe (1) contains ICU/Mechanical Ventilation/Intubation and Deceased. Influenza existence indicated whether individuals had Influenza (1) or not (0) from 01/01/2010, and Influenza counts indicated how many episodes of Influenza that individuals had from 01/01/2010. The upper layer ( a ) was for prior to COVID-19 metabolomic endotypes, while the lower layer ( b ) was for during/after COVID-19 metabolomic endotypes.

    Journal: eBioMedicine

    Article Title: The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases

    doi: 10.1016/j.ebiom.2023.104791

    Figure Lengend Snippet: Associations between COVID-19 severity and influenza infection with metabolomic endotypes . Chi-square tests determined the differences in clinical characteristics across metabolomic endotypes for categorical variables (COVID severity variables: severity, ICU admission, deceased; Influenza variable: Influenza existence) and one-way analysis of variance (ANOVA) tests for continuous variables (Influenza counts). Severity had four categories for a response after COVID-19 infection: No hospitalization, Inpatient/Emergency visit, ICU/Mechanical Ventilation/Intubation, and Deceased. The ICU Admission was a binary variable generated based on whether the patient had ICU admission or not: less severe (0) contained No hospitalization and Inpatient/Emergency visit, and more severe (1) contains ICU/Mechanical Ventilation/Intubation and Deceased. Influenza existence indicated whether individuals had Influenza (1) or not (0) from 01/01/2010, and Influenza counts indicated how many episodes of Influenza that individuals had from 01/01/2010. The upper layer ( a ) was for prior to COVID-19 metabolomic endotypes, while the lower layer ( b ) was for during/after COVID-19 metabolomic endotypes.

    Article Snippet: Untargeted global plasma metabolomic profiling was generated by Metabolon Inc. Coefficients of variation were measured in blinded quality control (QC) samples randomly distributed among study samples.

    Techniques: Infection, Generated

    Regression analysis results for the relationship between clinical phenotypes and metabolomic endotypes, including descriptive characteristics, comorbidity diseases, COVID-19 severity, influenza incidence and recurrence, and lab tests.

    Journal: eBioMedicine

    Article Title: The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases

    doi: 10.1016/j.ebiom.2023.104791

    Figure Lengend Snippet: Regression analysis results for the relationship between clinical phenotypes and metabolomic endotypes, including descriptive characteristics, comorbidity diseases, COVID-19 severity, influenza incidence and recurrence, and lab tests.

    Article Snippet: Untargeted global plasma metabolomic profiling was generated by Metabolon Inc. Coefficients of variation were measured in blinded quality control (QC) samples randomly distributed among study samples.

    Techniques: